Products Affected - Description

• • Basaglar Tempo Pen subcutaneous injection, Lilly USA, LLC, 100 units/mL, 3 mL pen injector, 5 count, NDC 00002-8214-05
  • Semglee subcutaneous injection, Biocon, 100 units/mL, 10 mL vial, NDC 83257-0011-11 - discontinued
  • Semglee Pen subcutaneous injection, Biocon, 100 units/mL, 3 mL pen injector, 5 count, NDC 83257-0012-33 - discontinued

Reason for the Shortage

• • Biocon discontinued Semglee vials and pens on December 31, 2025. The generic vials and pens are available.
  • Lilly has Basaglar and Rezvoglar Kwikpens available. Lilly is discontinuing Basaglar Tempo pens by the end of 2026 due to a business decision. Tempo pens are available through July 27, 2026. After that date, patients can use their Tempo Pens until the expiration date. However, the Tempo Platform will stop recording patient diabetes-related data on July 28, 2026. On December 31, 2026, the TempoSmart App and Tempo Insights portal will be discontinued. Additional information can be found at lillytempo.com.
  • Sanofi has Lantus available.
  • Winthrop has insulin glargine injection available.

Available Products

• • Basaglar Kwikpen subcutaneous injection, Lilly USA, LLC, 100 units/mL, 3 mL pen injector, 5 count, NDC 00002-7715-59
  • Insulin Glargine U-300 Max Solostar subcutaneous injection, Winthrop, 300 units/mL, 3 mL pen injector, 2 count, NDC 00955-2900-02
  • Insulin Glargine U-300 Solostar subcutaneous injection, Winthrop, 300 units/mL, 1.5 mL pen injector, 3 count, NDC 00955-3900-03
  • Lantus subcutaneous injection, Sanofi-Aventis, 100 units/mL, 10 mL vial, NDC 00088-2220-33
  • Lantus Solostar Pen subcutaneous injection, Sanofi-Aventis, 100 units/mL, 3 mL pen injector, 5 count, NDC 00088-2219-05
  • Rezvoglar Kwikpen subcutaneous injection, Lilly USA, LLC, 100 units/mL, 3 mL pen injector, 5 count, NDC 00002-8980-05
  • Toujeo 1.5 mL Prefilled Pen subcutaneous injection, Sanofi-Aventis, 300 units/mL, 1.5 mL pen injector, 3 count, NDC 00024-5869-03
  • Toujeo Max 3 mL Prefilled Pen subcutaneous injection, Sanofi-Aventis, 300 units/mL, 3 mL pen injector, 2 count, NDC 00024-5871-02
  • Insulin glargine-yfgn, recombinant subcutaneous injection, Biocon, 100 units/mL, 10 mL vial, NDC 83257-0014-11
  • Insulin glargine-yfgn, recombinant subcutaneous injection, Biocon, 100 units/mL, 3 mL pen injector, 5 count, NDC 83257-0015-32

• • Lilly is discontinuing Basaglar Tempo pens by the end of 2026. Tempo pens are available through July 27, 2026.

• • Patients on Basaglar Tempo pens should work with their healthcare provider to transition to Lilly insulin KwikPens or other insulin pens as soon as possible